Charles River Poster Presentations
Neuroscience 2018 was a forum for Charles River scientists to showcase key findings from independent and collaborative research efforts with top scientists from across the globe. This year, Charles River scientists presented 26 scientific posters alone and with clients. The presentations are listed below.
Alzheimer's Disease
- Effects of antioxidant in mouse model for Alzheimer’s: a behavioral phenotyping and microdialysis study
Marie Monbureau, Ayma F. Malik, Patrick J. Northey, Julien Roeser, Emily Holland, Claudio Ciardiello, Nadege Moristo, C. Zhu, Marieke van der Hart, Holden B. Janssens, Arash Rassoulpour
Charles River, South San Francisco, CA - Faster responding of Tg2576 mice in the touch screen version of the progressive ratio task
Joni Järvenpää1,2, Maksym V. Kopanitsa1,3, Jukka Puoliväli1
1Charles River, Kuopio, Finland; 2University of Eastern Finland, Kuopio, Finland; 3UK Dementia Research Institute, Imperial College, London, UK
Multiple Sclerosis
- An oral gavage model for cuprizone-induced brain demyelination: Improved repeatability along with robust and specific phenotype
Anna-Mari Kärkkäinen, Kimmo Lehtimäki, Anu Haapala, Teija Parkkari
Charles River, Kuopio, Finland - Neonatal hyperthyroidism induced developmental myelination model for multiple sclerosis
Karen Lariosa-Willingham1, Dmitri Leonoudakis1, Diana Miszczuk2; Kimmo Lehtimäki2, Laura Tolppanen2, Megan Flanagan3, Janelle Gibson3, Antti Nurmi2
1Teva Pharmaceutical Industries, Redwood City, CA, USA; 2Charles River, Kuopio, Finland; 3Sword Diagnostics, Chicago, IL, USA
Parkinson's Disease
- Acquisition and reversal of visual discrimination learning in MPTP-treated C57BL/6J mice
Joni Järvenpää1,1,2, Maksym V. Kopanitsa1,1,3, Artem Shatillo1, Jussi Rytkonen1, Lauri Remes1, Jukka Puoliväli1
1Charles River Discovery, Kuopio, Finland; 2University of Eastern Finland, Kuopio, Finland; 3UK Dementia Research Institute, Imperial College, London, UK - Assessment of the anti-parkinsonian effects of the potent and selective LRRK2 kinase inhibitor PF-360 in the AAV-A53T mouse model of Parkinson’s disease
Robert Hodgson1, Teija Parkkari1, Terina Martinez2, Matthew Fell3, Diane Bryce3, Taneli Heikkinen1, Timo Bragge1, Leena Tähtivaara1, Miia Taavitsainen1, James Koprich,5 Thomas Lanz4, Marco Baptista2
1Charles River Discovery, Kuopio, Finland; 2The Michael J Fox Foundation, New York, NY, USA; 3Merck & Co. Inc., Boston, MA, USA; 4Pfizer Inc, Cambridge, MA, USA; 5Atuka Inc, Toronto, Canada - Chronic treatment of LRRK2 inhibitors in diet produces an effect in the lung: Comparison of the effect in rats vs. mice
Robert Hodgson1, Teija Parkkari1, Terina Martinez2, Matthew Fell3, Diane Bryce3, Taneli Heikkinen1, James Baily5, Alys Bradley5, Jussi Rytkönen1, Miia Taavitsainen1, James Koprich,6 Thomas Lanz4, Marco Baptista2
1Charles River Discovery, Kuopio, Finland; 2The Michael J Fox Foundation, New York, NY, USA; 3Merck & Co. Inc., Boston, MA, USA; 4Pfizer Inc, Cambridge, MA, USA; 5Charles River Discovery, Edinburgh, UK; 6Atuka Inc, Toronto, Canada - Development and validation of a high content-based assay to measure Tom20 loss in dopaminergic human neurons differentiated
Raymond de Wit1, Folkert Verkaar1, Marc Watson2, Paul Thompson2 and Sipke Dijkstra1
1Charles River Laboratories, Darwinweg 24, 2333 CR, Leiden, The Netherlands; 2Mission Therapeutics, Babraham Research Park, Moneta (Building 280), Cambridge, CB 22 3AT, UK - Myricetin derivatives ameliorate deficits in 6-OHDA animal model of Parkinson's disease
Daryl Thompson1, Scott Truesdell1, Maksym Kopanitsa2,3, Diana Miszczuk2, Raimo Pussinen2, William Durham4, Paula Miliani de Marval4, Timothy Jensen4, Gunnar Flik5, Eileen Seward6, Peter Crackett6, Paul Bury6, Daniel Small7, Antti Nurmi2
1GRDG Sciences, LLC, Winter Haven, FL, USA; 2Charles River Discovery, Kuopio, Finland; 3UK Dementia Research Institute, Imperial College, London, UK; 4Charles River Discovery, Morrisville, NC, USA; 5Charles River Discovery, Groningen, Netherlands; 6Charles River Discovery, Harlow, UK; 7Charles River Laboratories, Wilmington, MA, USA - PR001 and PR002 modify motor phenotype in a rat model of Parkinson’s disease
Lysimachos Zografos1, J. Douglas Armstrong1, 2, 3, R. Wayne Davies1,2,3, Maksym Kopanitsa4,5, Timo Bragge4, Leena Tähtivaara4, Robert Hodgson4
1Parkure Ltd, Edinburgh, UK; 2Brainwave Discovery Ltd, Edinburgh, UK; 3University of Edinburgh, School of Informatics, Edinburgh, UK; 4Charles River Discovery, Kuopio, Finland; 5UK Dementia Research Institute, Imperial College, London, UK
Psychiatry
- Does ketamine really modulate glutamate?
Holden B. Janssens, Lisa Yu Harmen Kooijker, Bryson Cwick, Nadege Morisot, Julien Roeser, Marieke van der Hart, Arash Rassoulpour
Charles River, South San Francisco, CA - The development and utility of rodent paradigms to assess the activity of the vasopressin V1a receptor antagonists, balovaptan, and JNJ-17308616, in vivo
Diana Miszczuk1, Anna-Mari Kärkkäinen1, Stuart Robjohns2, Robert Hodgson1
1Charles River, Kuopio, Finland; 2Charles River, Saffron Walden, UK
Rare Disease
- Disease relevant in vitro assays for amytrophic lateral sclerosis in motor neurons derived from control and patient iPSCs
S. Jain1, M. BSIBSI1, M. JANUS1, J de Groot1, D.F. Fischer2 - Fine motor performance, brain volumetry and metabolism in Cln2R207X/R207X nonsense point mutation model for CLN2 Batten disease
Kimmo Lehtimäki1, Timo Bragge1, Jon Brudvig2, Tyler Johnson2, Derek Timm2, Antti Nurmi1, Jill Weimer2, Jukka Puoliväli1
1Charles River, Kuopio, Finland; 2Sanford Research, Sioux Falls, SD, USA - Longitudinal characterization of the Cln6nclf mouse model of CLN6 Batten disease — Characterization of fine motor performance, brain pathology and metabolic changes
Kimmo Lehtimäki1, Timo Bragge1, Tuulia Huhtala1, Maria Vihma1, Jon Brudvig2, Tyler Johnson2, Derek Timm2, Jukka Puoliväli1, Jussi Rytkönen1, Pekka Poutiainen3, Jill Weimer2, Antti Nurmi1
1Charles River Discovery, Kuopio, Finland; 2Sanford Research, Sioux Falls, SD, USA; 3Kuopio University Hospital, Kuopio, Finland - Principal component analysis (PCA)-based data fusion approach for a mouse model of CLN6 Batten disease
Timo Bragge1, Tuulia Huhtala1, Jukka Puoliväli1, Jon Brudvig2, Tyler Johnson2, Derek Timm2, Jussi Rytkönen1, Jill Weimer2, Antti Nurmi,1 Kimmo Lehtimäki1
1Charles River Discovery, Kuopio, Finland; 2Sanford Research, Sioux Falls, SD, USA
Stroke
- Functional imaging of thromboembolic stroke in rats using PET, ultrasound and MRI
Jussi Rytkönen1, Artem Shatillo1, Elina Latonummi1, Kimmo K. Lehtimäki1, Pekka Poutiainen2, Tuulia Huhtala1, Diana Miszczuk1, Antti Nurmi1
1Charles River Discovery, Kuopio, Finland; 2Kuopio University Hospital, Kuopio, Finland - Quantitative susceptibility mapping (QSM) MRI in a collagenase rat model of intracerebral hemorrhage (ICH)
Kimmo Lehtimäki, Artem Shatillo, Elina Latonummi, Antti Nurmi
Charles River, Kuopio, Finland
Technology
- Functional ultrasound — Novel in vivo imaging technique for pre-clinical CNS drug discovery
Artem Shatillo, Tuukka Miettinen, Juho Koponen, Anna-Mari Kärkkäinen, Diana Miszczuk, Antti Nurmi
Charles River, Kuopio, Finland - Translational PET imaging of neuroinflammation in pre-clinical rodent models of neurogenerative diseases
Jussi Rytkönen1, Pekka Poutiainen2, Diana Miszczuk1, Antti Nurmi1, Tuulia Huhtala1
1Charles River Discovery, Kuopio, Finland; 2Kuopio University Hospital, Kuopio, Finland - Volumetric analysis of hexachlorophene-treated rats by MRM and stereology for neuropathology
M. A. STAUP1, D. BROWN1, C. JOHNSON1, P. LITTLE2, R. SILLS3, G. A. JOHNSON4;
1Pathology, Charles River, Durham, NC; 2Exptl. Pathology Laboratories, Inc., Durham, NC; 3Cell. and Mol. Pathology for the Natl. Toxicology Program, Natl. Inst. of Envrn. Hlth. Sci., Durham, NC; 4Duke Ctr. for In Vivo Microscopy, Duke Univ., Durham, NC
Learn How We Can Support You Through The Entire Neuroscience Research Process